Patients’ attitudes and preferences toward delayed disease progression in the absence of improved survival

Abstract

Prolongation of time to progression was not universally valued. Most patients did not prefer treatments that negatively affect quality of life for PFS gains alone. Implications for individual decision making, policy, and trials research are discussed.